The present study examines the relationship of the hypothalamic paraventricular nucleus (PVN) to discrete brain and pituitary pools of immunoreactive (ir) vasopressin (VP), oxytocin (OT) and particular opioid peptides in the rat. Selective, bilateral destruction of the PVN resulted in a parallel depression in levels of ir-VP, ir-OT, ir-dynorphin (DYN), ir-DYN1–8 and ir-α-neo-endorphin (α-NE) in the neurointermediate lobe of the pituitary, whereas in its anterior counterpart no decrease in the content of any of these peptides was seen. In contrast, the content of ir-β-endorphin (β-EP) in the neurointermediate lobe was not significantly altered. Further, a rise in levels of ir-β-EP in the anterior lobe, together with a fall in these in systemic plasma, was found. In the hypothalamus, in distinction to ir-metenkephalin (ME), a diminution in the content of ir-VP, ir-OT, ir-DYN, ir-DYN1–8, ir-α-NE and, in addition, ir-β-EP was observed. In the septum, midbrain and medulla/pons, however, a selective depression in levels of ir-VP (and, as measured in the medulla/pons, of ir-OT) was seen: the content of ir-DYN, ir-DYN1–8, ir-α-NE, ir-β-EP and ir-ME was unchanged in these tissues. These data indicate that: (1) the PVN is an important contributor to neurointermediate lobe, but not anterior lobe, pools of ir-VP, ir-OT, ir-DYN, ir-DYN1–8 and ir-α-NE in contrast to ir-β-EP. (2) the PVN provides a mayor input of ir-VP (and ir-OT), in contrast to ir-DYN, ir-DYN1–8, ir-α-NE, ir-β-EP and ir-ME, to the septum, midbrain and medulla pons. (3) although coexisting with ir-VP in a hypothalamo-neural lobe tract partially derived from the PVN, ir-DYN, ir-DYN1–8 and ir-α-NE exist independently of the PVN-originating VP-containing neurons which innervate extrahypothalamic brain tissue. (4) the PVN may interact with hypothalamic ir-β-EP and plays a facilitatory role in the tonic regulation of adenohypophyseal secretion of ir-β-EP into the systemic circulation.

Keywords:
Vasopressin, Oxytocin, Dynorphin, α-Neo-endorphin, β-Endorphin, Met-enkephalin, Paraventricular nucleus
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.